Cover Image
市場調查報告書

全球潛血檢查市場預測:各國檢查數量,銷售額預測及供應商的市場佔有率

Occult Blood Testing Market 2021: US, Europe, Japan--Emerging Opportunities, Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Technologies and Opportunities

出版商 Venture Planning Group 商品編碼 237648
出版日期 內容資訊 英文 243 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球潛血檢查市場預測:各國檢查數量,銷售額預測及供應商的市場佔有率 Occult Blood Testing Market 2021: US, Europe, Japan--Emerging Opportunities, Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Technologies and Opportunities
出版日期: 內容資訊: 英文 243 Pages
簡介

本報告提供全球主要國家(法國、德國、義大利、日本、西班牙、英國、美國)的潛血檢查市場相關調查分析,提供全球市場及技術概要,各國市場的現況與未來預測,主要的產品開發機會,打入市場策略等驗證,也包含主要企業簡介,為您概述為以下內容。

目錄

I. 簡介

II. 全球市場及技術概要

A. 潛血: 臨床意義及檢驗實習

B. 設備、設備類 概論及市場需求

  • 1. Abbott AxSYM
  • 2. Abbott IMx
  • 3. Anagen AN2000/AuraFlex
  • 4. Beckman Coulter Access
  • 5. BioChem Pharma SR1
  • 6. bioMerieux Vidas Series
  • 7. Biotrol Systems 7000
  • 8. J&J Diagonostics/Amersham Amerlite
  • 9. J&J Diagonostics Vitros ECI
  • 10. Olympus PK Series
  • 11. Roche Cobas Core
  • 12. Roche Elecsys
  • 13. Roche ES 22
  • 14. Roche ES 33
  • 15. Roche ES 300/300 AL
  • 16. Siemens ACS: 180
  • 17. Siemens ACS: Centaur
  • 18. Siemens ELISA Processor II/III
  • 19. Siemens Immuno 1
  • 20. Siemens/Opus/Plus/Magnum
  • 21. Siemens Stratus
  • 22. Tosoh AIA Series
  • 23. Wallac/Pharmacia Delfia elfia

C. 最新技術

  • 1. 單株與多株抗體
  • 2. 免疫疾病學的檢測法
  • 3. 分子診斷檢驗
  • 4. 生物晶片/微陣列
  • 5. 染色體分析
  • 6. 微電腦及自動化
  • 7. 人工智能
  • 8. 流式細胞技術
  • 9. 生物感應器

D. 競爭/補充的技術

  • 1. CT
  • 2. MRI
  • 3. NMR
  • 4. PET
  • 5.Photonics Spectroscopy

E. 個人檢驗

III. 法國: 檢查數量及診斷用藥 銷售額預測 (各市場區隔)

IV. 德國: 檢查數量及診斷用藥 銷售額預測 (各市場區隔)

V. 義大利: 檢查數量及診斷用藥 銷售額預測 (各市場區隔)

VI. 日本: 檢查數量及診斷用藥 銷售額預測 (各市場區隔)

VII. 西班牙: 檢查數量及診斷用藥 銷售額預測 (各市場區隔)

VIII. 英國: 檢查數量及診斷用藥 銷售額預測 (各市場區隔)

IX. 美國: 檢查數量及診斷用藥 銷售額預測 (各市場區隔)

X. 分散式檢查產品的設計標準

XI. 替代市場滲透策略

  • A. 內部開發
  • B. 共同開發
  • C. 跟大學的合作
  • D. 流通策略
    • 1. 行銷方法
    • 2. 產品的電子處方的複雜性
    • 3. 客戶偏好
    • 4. 確立的供給業者
    • 5. 新供給業者
    • 6. 主要類型的批發業者
    • 7. 市場細分化因素

XII. 潛在市場進入障礙及風險

  • A. 市場的成熟度
  • B. 成本控制
  • C. 競爭
  • D. 技術方面的優勢與限制
  • E. 專利保護
  • F. 法規限制
  • G. 分散式檢查市場課題

XIII. 競爭簡介

  • Abbott
  • AdnaGen
  • Ambrilia Biopharma
  • AMDL
  • Beckman Coulter
  • Becton Dickinson
  • Biomedica Diagonostics
  • bioMerieux
  • Bio-Rad
  • CanAG Diagonostics
  • CeMines
  • Cepheid
  • Correlogic Systems
  • Dako
  • Decode
  • Diadexus
  • Diagnocure
  • Diasorin
  • Eiken Chemical
  • Enterix
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Gen-Probe
  • Guided Therapeutics
  • Hologic
  • Ipsogen
  • J&J Diagonostics
  • Kreatech
  • Kyowa Medex
  • Mackay Life Sciences
  • Matritech
  • Myriad Genetics
  • OncoLab
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • Takara Bio
  • Targeted Diagonostics & Therapeutics
  • Tosoh
  • Veridex
  • Wako Pure Chemicals
  • Wallac
  • Zila

表格一覽

  • 主要的開發/銷售企業; 潛血 檢驗
  • 法國 潛血 檢查數量及診斷用藥 (各市場區隔)
  • 德國 潛血 檢查數量及診斷用藥 (各市場區隔)
  • 義大利 潛血 檢查數量及診斷用藥 (各市場區隔)
  • 日本 潛血 檢查數量及診斷用藥 (各市場區隔)
  • 西班牙 潛血 檢查數量及診斷用藥 (各市場區隔)
  • 英國 潛血 檢查數量及診斷用藥 (各市場區隔)
  • U.S.A 潛血 檢查數量及診斷用藥 (各市場區隔)

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: VPCA26497

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

This report presents a detailed analysis of the Occult Blood testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.

The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 243 pages and 8 tables

Table of Contents

I. Introduction

II. OCCULT BLOOD Worldwide Market and Technology Overview

A. Occult Blood: Clinical Significance and Laboratory Practices

B. Instrumentation Review And Market Needs

  • 1. Abbott AxSYM
  • 2. Abbott Architect c4000
  • 3. Abbott Architect i2000 Series
  • 4. Abbott Architect ci8200 System
  • 5. Beckman Coulter UniCel Series
  • 6. Beckman Coulter Access
  • 7. Binding Site ESP600
  • 8. bioMerieux Mini Vidas
  • 9. Carolina Chemistries BioLis 24i
  • 10. DiaSorin Liaison
  • 11. Horiba ABX Pentra 400
  • 12. Inverness DS2
  • 13. J&J Vitros ECi/ECiQ
  • 14. J&J Vitros 3600
  • 15. J&J Vitros 5600
  • 16. Olympus AU5400
  • 17. Olympus AU3000i
  • 18. Olympus AU2700
  • 19. Roche Modular Analytics
  • 20. Roche Cobas Integra 400
  • 21. Roche Cobas Integra 400 Plus
  • 22. Roche Elecsys
  • 23. Roche Cobas c311
  • 24. Siemens ADVIA Centaur
  • 25. Siemens Dimension
  • 26. Siemens Dimension RxL Max
  • 27. Siemens Dimension Vista 500
  • 28. Siemens Immulite
  • 29. Siemens Stratus
  • 30. Tosoh AIA-Series
  • 31. Vital Diagnostics ATAC 8000
  • 32. Vital Diagnostics Envoy 500

C. Current and Emerging Technologies

  • 1. Monoclonal and Polyclonal Antibodies
  • 2. Immunoassays
    • a. Technological Principle
    • b. Radioimmunoassay (RIA)
    • c. Enzyme Immunoassays (EIA)
      • Overview
      • ELISA
      • Immunofiltration
      • Particle-Membrane Capture Immunoassay
      • Enzyme Amplification
    • d. Fluorescent Immunoassays
    • e. Luminescence
      • Chemiluminescence
      • Bioluminescence
    • f. Latex Agglutination
    • g. Immunoprecipitation
    • H. Affinity Chromatographu
    • e. Liposome Flow-Injection Immunoassay
  • 3. Molecular Diagnostics
    • a. Technology Overview
    • b. Amplification Methods
      • PCR
      • DAP-PCR
      • Immuno-PCR
      • QC-PCR
      • CAR
      • DNA
      • HPA
      • LCR
      • NASBA
      • QBR
      • SDA
      • 3 SR, and others
  • 4. Chromosome Analysis
    • a. Chronic Myelogenous Leukemia (CML)
    • b. Acute Myeloid Leukemia (AML)
    • c. Acute Lymphoblastic Leukemia (ALL)
    • d. Malignant Lymphomas
    • Lymphoid Malignancies
    • e. Chronic Lymphocytic Leukemia (CLL)
    • f. Solid Cancers
    • g. Chromosomal Translocation and Oncogenes
  • 5. Artificial Intelligence
  • 6. Flow Cytometry
  • 7. Two Dimensional Gel Electrophoresis (2-DGE)
  • 8. Biosensors
  • 9. Competing/Complementing Technologies
    • a. CT
    • b. MRI
    • c. NMR
    • d. PET
    • e. Photonics Spectroscopy

E. Personal Testing

III. France: Test Volume and Diagnostics Sales Forecast by Market Segment

IV. Germany: Test Volume and Diagnostics Sales Forecast by Market Segment

V. Italy: Test Volume and Diagnostics Sales Forecast by Market Segment

VI. Japan: Test Volume and Diagnostics Sales Forecast by Market Segment

VII. Spain: Test Volume and Diagnostics Sales Forecast by Market Segment

VIII. U.K.: Test Volume and Diagnostics Sales Forecast by Market Segment

IX. U.S.A.: Test Volume and Diagnostics Sales Forecast by Market Segment

X. Design Criteria for Decentralized Testing Products

XI. Alternative Market Penetration Strategies

  • A. Internal Development
  • B. Collaborative Arrangements
  • C. University Contracts
  • D. Distribution Strategies
    • 1. Marketing Approaches
    • 2. Product Complexity
    • 3. Customer Preference
    • 4. Established Suppliers
    • 5. Emerging Suppliers
    • 6. Major Types of Distributors
    • 7. Market Segmentation Factor

XII. Potential Market Entry Barriers and Risks

  • A. Market Maturity
  • B. Cost Containment
  • C. Competition
  • D. Technological Edge and Limitations
  • E. Patent Protection
  • F. Regulatory Constraints
  • G. Decentralized Testing Market Challenges

XIII. Competitive Profiles

  • Abbott
  • AdnaGen
  • Applied Gene Technologies
  • Arca
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Correlogic Systems
  • Dako
  • Decode
  • Diadexus
  • Diagnocure
  • Diasorin
  • Eiken Chemical
  • Enterix
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Gen-Probe
  • Guided Therapeutics
  • Hologic
  • Ipsogen
  • Kreatech
  • Kyowa Medex
  • Life Technologies
  • Mackay Life Sciences
  • Myriad Genetics
  • Nanogen Elitech
  • OncoLab
  • Ortho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • Takara Bio
  • Targeted Diagnostics & Therapeutics
  • Tosoh
  • Veridex
  • Wako Pure Chemicals
  • Wallac/PE
  • Zila

List of Tables

  • Major Companies Developing or Marketing Occult Blood Tests
  • France Occult Blood Test Volume and Diagnostics Sales by Market Segment
  • Germany Occult Blood Test Volume and Diagnostics Sales by Market Segment
  • Italy Occult Blood Test Volume and Diagnostics Sales by Market Segment
  • Japan Occult Blood Test Volume and Diagnostics Sales by Market Segment
  • Spain Occult Blood Test Volume and Diagnostics Sales by Market Segment
  • U.K. Occult Blood Test Volume and Diagnostics Sales by Market Segment
  • U.S.A Occult Blood Test Volume and Diagnostics Sales by Market Segment
Back to Top